Home / FAQ / ProCellEx® Platform

ProCellEx® Platform

Establishment of a tobacco BY2 cell line devoid of plant-specific xylose and fucose as a platform for the production of biotherapeutic proteins.

Hanania U, Ariel T, Tekoah Y, Fux L, Sheva M, Gubbay Y, Weiss M, Oz D, Azulay Y, Turbovski A, Forster Y, Shaaltiel Y.

Plant Biotechnol J. 2017(pp.1-10)

Plant specific N-glycans do not have proven adverse effects in humans.

Shaaltiel Y, Tekoah Y.

Nat Biotechnol. 2016 Jul(pp,.1-3)

Large-scale production of pharmaceutical proteins in plant cell culture-the Protalix experience.

Tekoah Y, Shulman A, Kizhner T, Ruderfer I, Fux L, Nataf Y, Bartfeld D, Ariel T, Gingis-Velitski S, Hanania U, Shaaltiel Y.

Plant Biotechnol J. 2015(pp.1-10)

Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R.

Atsmon J, Brill-Almon E, Nadri-Shay C, Chertkoff R, Alon S, Shaikevich D, Volokhov I, Haim KY, Bartfeld D, Shulman A, Ruderfer I, Ben-Moshe T, Shilovitzky O, Soreq H, Shaaltiel Y.

Toxicol Appl Pharmacol. 2015(pp.1-10)

Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher’s disease.

Shaaltiel Y, Gingis-Velitski S, Tzaban S, Fiks N, Tekoah Y, Aviezer D.

Plant Biotechnol J. 2015(pp.1-8)